Metraipolis › archive › dc_32ebf7bab202
MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression — Europe PMC PMID:41053077
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41053077
- DOI
- 10.1038/s41419-[numero omesso]-7
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T13:41:56.758Z
- SHA-256 of the archived text
9fc5e5df0e51b19e51a4e1fea9f87bffe2b9d06524e0c7ec24e698c8cf468078- Stable URL of this page
https://metraipolis.com/documento/dc_32ebf7bab202
How to cite
MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression — Europe PMC PMID:41053077 — Europe PMC (en), https://europepmc.org/article/MED/41053077 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_32ebf7bab202 (Metraipolis archive dc_32ebf7bab202, sha256 9fc5e5df0e51b19e51a4e1fea9f87bffe2b9d06524e0c7ec24e698c8cf468078)
BibTeX
@misc{dc32ebf7bab202,
title = {MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression — Europe PMC PMID:41053077},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41053077},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_32ebf7bab202; sha256 9fc5e5df0e51b19e51a4e1fea9f87bffe2b9d06524e0c7ec24e698c8cf468078},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41053077. Agents can read the archived copy with the MCP tool read_document.